Michael M Gottesman

List of Publications by Citations

214 papers	35,514 citations	71 h-index	188 g-index
229 ext. papers	38,118 ext. citations	8.9 avg, IF	7.35 L-index

#	Paper	IF	Citations
214	Multidrug resistance in cancer: role of ATP-dependent transporters. *Nature Reviews Cancer*, **2002**, 2, 48-58	31.3	4255
213	Biochemistry of multidrug resistance mediated by the multidrug transporter. *Annual Review of Biochemistry*, **1993**, 62, 385-427	29.1	3184
212	Targeting multidrug resistance in cancer. *Nature Reviews Drug Discovery*, **2006**, 5, 219-34	64.1	2649
211	Mechanisms of cancer drug resistance. *Annual Review of Medicine*, **2002**, 53, 615-27	17.4	1958
210	A "silent" polymorphism in the MDR1 gene changes substrate specificity. *Science*, **2007**, 315, 525-8	33.3	1928
209	Biochemical, cellular, and pharmacological aspects of the multidrug transporter. *Annual Review of Pharmacology and Toxicology*, **1999**, 39, 361-98	17.9	1787
208	Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. *Cell*, **1986**, 47, 381-9	56.2	1743
207	Expression of a multidrug resistance gene in human cancers. *Journal of the National Cancer Institute* , **1989**, 81, 116-24	9.7	1087
206	P-glycoprotein: from genomics to mechanism. *Oncogene*, **2003**, 22, 7468-85	9.2	847
205	Revisiting the role of ABC transporters in multidrug-resistant cancer. *Nature Reviews Cancer*, **2018**, 18, 452-464	31.3	732
204	Is the multidrug transporter a flippase?. *Trends in Biochemical Sciences*, **1992**, 17, 18-21	10.3	636
203	Multiple-drug resistance in human cancer. *New England Journal of Medicine*, **1987**, 316, 1388-93	59.2	618
202	Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. *Pharmacological Reviews*, **2012**, 64, 706-21	22.5	565
201	HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. *Biochemistry*, **1998**, 37, 3594-601	3.2	453
200	Mechanisms of multidrug resistance in cancer. *Methods in Molecular Biology*, **2010**, 596, 47-76	1.4	450
199	Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. *Cancer Cell*, **2004**, 6, 129-37	24.3	432
198	Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. *Somatic Cell and Molecular Genetics*, **1985**, 11, 117-26		413

197	The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. *FEBS Letters*, **2006**, 580, 998-1009	3.8	380
196	The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. *Annual Review of Pharmacology and Toxicology*, **2008**, 48, 495-535	17.9	374
195	The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. *Biochemical and Biophysical Research Communications*, **1986**, 141, 956-62	3.4	350
194	The clinical relevance of cancer cell lines. *Journal of the National Cancer Institute*, **2013**, 105, 452-8	9.7	341
193	Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 18708-13	11.5	311
192	Overview: ABC transporters and human disease. *Journal of Bioenergetics and Biomembranes*, **2001**, 33, 453-8	3.7	261
191	A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2009**, 1794, 860-71	4	239
190	Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. *Biochemistry*, **1998**, 37, 5010-9	3.2	229
189	Collateral sensitivity as a strategy against cancer multidrug resistance. *Drug Resistance Updates*, **2012**, 15, 98-105	23.2	215
188	Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. *Cancer Research*, **2014**, 74, 3913-22	10.1	208
187	Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. *Journal of the National Cancer Institute*, **2010**, 102, 1637-52	9.7	208
186	Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 7449-54	11.5	206
185	Toward a Better Understanding of the Complexity of Cancer Drug Resistance. *Annual Review of Pharmacology and Toxicology*, **2016**, 56, 85-102	17.9	200
184	Is resistance useless? Multidrug resistance and collateral sensitivity. *Trends in Pharmacological Sciences*, **2009**, 30, 546-56	13.2	195
183	Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. *Journal of Molecular Biology*, **2008**, 383, 281-91	6.5	195
182	Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. *Cancer Research*, **2007**, 67, 9609-12	10.1	194
181	ATP-binding properties of P glycoprotein from multidrug-resistant KB cells. *FASEB Journal*, **1987**, 1, 51-4	0.9	194
180	CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered beta-tubulin. *Cell*, **1980**, 20, 29-36	56.2	189

179	Drug resistance: still a daunting challenge to the successful treatment of AML. *Drug Resistance Updates*, **2012**, 15, 62-9	23.2	183
178	P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. *Biochemical and Biophysical Research Communications*, **1989**, 162, 224-31	3.4	171
177	Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. *Cancer Research*, **2006**, 66, 4808-15	10.1	148
176	Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. *Molecular Pharmacology*, **2002**, 62, 1-6	4.3	147
175	Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. *Journal of Biological Chemistry*, **1996**, 271, 1708-16	5.4	146
174	Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 9903-7	11.5	145
173	Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. *Chemical Reviews*, **2014**, 114, 5753-74	68.1	140
172	Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein. *Journal of Biological Chemistry*, **1996**, 271, 1877-83	5.4	134
171	Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. *Molecular Cancer Therapeutics*, **2008**, 7, 3081-91	6.1	130
170	Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy. *Blood*, **1999**, 94, 52-61	2.2	130
169	The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). *ACS Chemical Neuroscience*, **2011**, 2, 82-9	5.7	129
168	Both ATP sites of human P-glycoprotein are essential but not symmetric. *Biochemistry*, **1999**, 38, 13887-99	3.2	129
167	Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. *Journal of Urology*, **1988**, 139, 862-5	2.5	129
166	Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells. *Journal of Medicinal Chemistry*, **2009**, 52, 3191-204	8.3	125
165	Expression of the human multidrug transporter in insect cells by a recombinant baculovirus. *Biochemistry*, **1990**, 29, 2295-303	3.2	125
164	Genetic basis of multidrug resistance of tumor cells. *Journal of Bioenergetics and Biomembranes*, **1990**, 22, 593-618	3.7	124
163	Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. *Pigment Cell and Melanoma Research*, **2009**, 22, 740-9	4.5	121
162	DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus. *Nature Genetics*, **1997**, 17, 483-6	36.3	121

161	Structures of the Multidrug Transporter P-glycoprotein Reveal Asymmetric ATP Binding and the Mechanism of Polyspecificity. *Journal of Biological Chemistry*, **2017**, 292, 446-461	5.4	120
160	Expression of the multidrug resistance gene in myeloid leukemias. *Leukemia Research*, **1990**, 14, 11-21	2.7	102
159	MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. *Cancer Research*, **2014**, 74, 598-608	10.1	93
158	Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport. *Biochemistry*, **1998**, 37, 13660-73	3.2	93
157	Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein. *Journal of Medicinal Chemistry*, **2011**, 54, 5878-89	8.3	86
156	SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. *Molecular Cancer Research*, **2008**, 6, 1499-506	6.6	84
155	Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. *Cancer Research*, **2012**, 72, 5945-55	10.1	83
154	Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. *FASEB Journal*, **2000**, 14, 516-22	0.9	83
153	Interaction of bioactive hydrophobic peptides with the human multidrug transporter. *FASEB Journal*, **1994**, 8, 766-70	0.9	82
152	Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. *Molecular Cancer Therapeutics*, **2007**, 6, 3287-96	6.1	80
151	Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. *Journal of Cellular Physiology*, **2000**, 183, 108-16	7	80
150	Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein. *Biochemistry*, **1998**, 37, 16400-9	3.2	79
149	Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. *Pharmacogenomics*, **2007**, 8, 29-39	2.6	78
148	The Inhibitor Ko143 Is Not Specific for ABCG2. *Journal of Pharmacology and Experimental Therapeutics*, **2015**, 354, 384-93	4.7	77
147	The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	73
146	A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1). *Trends in Pharmacological Sciences*, **2005**, 26, 385-7	13.2	73
145	Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. *Molecular Pharmacology*, **2004**, 66, 1397-405	4.3	73
144	The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi-drug transporter. *International Journal of Cancer*, **1993**, 54, 456-61	7.5	73

143	The dynamics of drug resistance: a mathematical perspective. *Drug Resistance Updates*, **2012**, 15, 90-7	23.2	71
142	Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. *Journal of the National Cancer Institute*, **1991**, 83, 1386-91	9.7	70
141	Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. *Cancer Research*, **2003**, 63, 5909-16	10.1	70
140	Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. *PLoS ONE*, **2012**, 7, e40717	3.7	66
139	Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. *Pigment Cell & Melanoma Research*, **2005**, 18, 102-12		65
138	Influence of melanosome dynamics on melanoma drug sensitivity. *Journal of the National Cancer Institute*, **2009**, 101, 1259-71	9.7	64
137	Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. *ACS Nano*, **2013**, 7, 10452-64	16.7	63
136	Beyond 3D culture models of cancer. *Science Translational Medicine*, **2015**, 7, 283ps9	17.5	62
135	Cryo-EM Analysis of the Conformational Landscape of Human P-glycoprotein (ABCB1) During its Catalytic Cycle. *Molecular Pharmacology*, **2016**, 90, 35-41	4.3	59
134	Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. *Molecular Pharmacology*, **2004**, 66, 789-93	4.3	58
133	Cancer gene therapy: an awkward adolescence. *Cancer Gene Therapy*, **2003**, 10, 501-8	5.4	57
132	A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol. *Biochemistry*, **1999**, 38, 6630-9	3.2	54
131	Endocytic recycling compartments altered in cisplatin-resistant cancer cells. *Cancer Research*, **2006**, 66, 2346-53	10.1	53
130	P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. *Cancer Research*, **2003**, 63, 3084-91	10.1	53
129	Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. *Current Pharmaceutical Biotechnology*, **2011**, 12, 686-92	2.6	52
128	Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum. *Journal of Cellular Physiology*, **2005**, 202, 635-41	7	51
127	Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site. *Nature Biotechnology*, **1994**, 12, 694-8	44.5	50
126	Molecular manipulations of the multidrug transporter: a new role for transgenic mice. *FASEB Journal*, **1991**, 5, 2523-8	0.9	50

125	Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with Pseudomonas exotoxin. *Journal of Cellular Physiology*, **1984**, 120, 271-9	7	49
124	The role of cell density and intratumoral heterogeneity in multidrug resistance. *Cancer Research*, **2013**, 73, 7168-75	10.1	47
123	Genetic evidence that a phorbol ester tumor promoter stimulates ornithine decarboxylase activity by a pathway that is independent of cyclic AMP-dependent protein kinases in CHO cells. *Journal of Cellular Physiology*, **1982**, 113, 433-9	7	46
122	A dual-fluorescence high-throughput cell line system for probing multidrug resistance. *Assay and Drug Development Technologies*, **2009**, 7, 233-49	2.1	45
121	Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. *Proceedings of the National Academy of Sciences of the United States of America* , **2011**, 108, 2593-8	11.5	45
120	Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. *Clinical Cancer Research*, **2012**, 18, 3197-206	12.9	41
119	Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. *Cancer Research*, **2012**, 72, 2350-61	10.1	41
118	Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. *Molecular Pharmaceutics*, **2006**, 3, 87-93	5.6	40
117	New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene. *Journal of Urology*, **1991**, 146, 447-53	2.5	40
116	Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein. *Drug Metabolism and Disposition*, **2016**, 44, 275-82	4	39
115	High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences. *Human Gene Therapy*, **2003**, 14, 167-77	4.8	39
114	Defeating drug resistance in cancer. *Discovery Medicine*, **2006**, 6, 18-23	2.5	39
113	Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 3123-8	11.5	37
112	Retroviral transfer of a chimeric multidrug resistance-adenosine deaminase gene. *FASEB Journal*, **1990**, 4, 1501-7	0.9	36
111	N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. *Drug Metabolism and Disposition*, **2010**, 38, 917-22	4	35
110	In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer. *Human Gene Therapy*, **2002**, 13, 299-310	4.8	35
109	Transfer of genes to Chinese hamster ovary cells by DNA-mediated transformation. *Somatic Cell Genetics*, **1982**, 8, 23-39		35
108	Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. *Molecular Cancer Therapeutics*, **2009**, 8, 2057-66	6.1	34

107	Regulation and expression of the ATP-binding cassette transporter ABCG2 in human embryonic stem cells. *Stem Cells*, **2012**, 30, 2175-87	5.8	33
106	Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 20801-6	11.5	33
105	Characterization by somatic cell genetics of a monoclonal antibody to the MDR1 gene product (P-glycoprotein): determination of P-glycoprotein expression in multi-drug-resistant KB and CEM cell variants. *International Journal of Cancer*, **1991**, 47, 533-43	7.5	33
104	Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity. *Cancer*, **2013**, 119, 3076-83	6.4	32
103	Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. *Journal of Medicinal Chemistry*, **2011**, 54, 4987-97	8.3	32
102	Studies of human MDR1-MDR2 chimeras demonstrate the functional exchangeability of a major transmembrane segment of the multidrug transporter and phosphatidylcholine flippase. *Molecular and Cellular Biology*, **1999**, 19, 1450-9	4.8	32
101	Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice. *Journal of Urology*, **1993**, 149, 174-8	2.5	32
100	Gene transfer of drug resistance genes. Implications for cancer therapy. *Annals of the New York Academy of Sciences*, **1994**, 716, 126-38; discussion 138-43	6.5	32
99	Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells. *Cancer Letters*, **2019**, 457, 110-118	9.9	31
98	Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tiopronin. *Journal of Biological Chemistry*, **2014**, 289, 21473-89	5.4	31
97	ATP and GTP as alternative energy sources for vinblastine transport by P-170 in KB-V1 plasma membrane vesicles. *FEBS Letters*, **1992**, 304, 256-60	3.8	31
96	The impact of cell density and mutations in a model of multidrug resistance in solid tumors. *Bulletin of Mathematical Biology*, **2014**, 76, 627-53	2.1	30
95	The extracellular loop between TM5 and TM6 of P-glycoprotein is required for reactivity with monoclonal antibody UIC2. *Archives of Biochemistry and Biophysics*, **1999**, 367, 74-80	4.1	30
94	Reduced mRNA levels for the multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines. *Journal of Cellular Physiology*, **1992**, 152, 87-94	7	30
93	The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity. *Molecular Cancer Therapeutics*, **2015**, 14, 90-100	6.1	29
92	Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. *Molecular Pharmaceutics*, **2011**, 8, 2080-8	5.6	28
91	P-Glycoprotein is not present in mitochondrial membranes. *Experimental Cell Research*, **2007**, 313, 3100-5	4.2	28
90	Identification of Cytoskeletal [14C]Carboplatin-Binding Proteins Reveals Reduced Expression and Disorganization of Actin and Filamin in Cisplatin-Resistant Cell Lines. *Molecular Pharmacology*, **2004**, 66, 789-793	4.3	27

89	Multidrug resistant transgenic mice as a novel pharmacologic tool. *BioEssays*, **1991**, 13, 381-7	4.1	27
88	The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer. *Methods in Molecular Biology*, **2009**, 542, 5-54	1.4	27
87	Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. *Journal of Cellular Physiology*, **2010**, 225, 822-8	7	26
86	Detection of multidrug resistance (MDR1) gene RNA expression in human tumors by a sensitive ribonuclease protection assay. *Japanese Journal of Cancer Research*, **1989**, 80, 1127-32		26
85	Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance. *Molecular Pharmacology*, **2006**, 69, 1383-8	4.3	25
84	A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. *Journal of Inorganic Biochemistry*, **2004**, 98, 1599-606	4.2	25
83	Pluripotent Stem Cell Platforms for Drug Discovery. *Trends in Molecular Medicine*, **2018**, 24, 805-820	11.5	24
82	RAB8 enhances TMEM205-mediated cisplatin resistance. *Pharmaceutical Research*, **2012**, 29, 643-50	4.5	24
81	Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. *Experimental Cell Research*, **2004**, 293, 283-91	4.2	24
80	Heterogeneity in refractory acute myeloid leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 10494-10503	11.5	22
79	Modeling intrinsic heterogeneity and growth of cancer cells. *Journal of Theoretical Biology*, **2015**, 367, 262-277	2.3	22
78	Microfabricated polymeric vessel mimetics for 3-D cancer cell culture. *Biomaterials*, **2013**, 34, 8301-13	15.6	22
77	Model systems for studying the blood-brain barrier: Applications and challenges. *Biomaterials*, **2019** , 214, 119217	15.6	21
76	A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. *Molecular Pharmacology*, **2016**, 89, 263-72	4.3	21
75	Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells. *Experimental Cell Research*, **2013**, 319, 566-74	4.2	19
74	Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL. *Experimental Cell Research*, **2015**, 336, 318-28	4.2	18
73	Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. *Journal of Cellular Physiology*, **1993**, 155, 414-25	7	18
72	Mathematical Modeling Reveals That Changes to Local Cell Density Dynamically Modulate Baseline Variations in Cell Growth and Drug Response. *Cancer Research*, **2016**, 76, 2882-90	10.1	17

71	P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway. *Biochemical Pharmacology*, **2013**, 86, 584-96	6	17
70	Sodium butyrate affects expression of fibronectin on CHO cells: specific increase in antibody-complement-mediated cytotoxicity. *Journal of Cellular Physiology*, **1980**, 104, 163-70	7	17
69	The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans. *PLoS Medicine*, **2015**, 12, e1001782	11.6	16
68	A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer. *Experimental Cell Research*, **2020**, 388, 111860	4.2	16
67	An automated method measures variability in P-glycoprotein and ABCG2 densities across brain regions and brain matter. *Journal of Cerebral Blood Flow and Metabolism*, **2017**, 37, 2062-2075	7.3	15
66	Simplifying the complexity of resistance heterogeneity in metastasis. *Trends in Molecular Medicine*, **2014**, 20, 129-36	11.5	14
65	Inhibition of multidrug resistance by SV40 pseudovirion delivery of an antigene peptide nucleic acid (PNA) in cultured cells. *PLoS ONE*, **2011**, 6, e17981	3.7	14
64	Down-regulation and altered localization of gamma-catenin in cisplatin-resistant adenocarcinoma cells. *Molecular Pharmacology*, **2004**, 65, 1217-24	4.3	14
63	The molecular mysteries underlying P-glycoprotein-mediated multidrug resistance. *Cancer Biology and Therapy*, **2004**, 3, 382-4	4.6	14
62	Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs. *Journal of Biological Inorganic Chemistry*, **2015**, 20, 1081-95	3.7	13
61	Mapping discontinuous epitopes for MRK-16, UIC2 and 4E3 antibodies to extracellular loops 1 and 4 of human P-glycoprotein. *Scientific Reports*, **2018**, 8, 12716	4.9	12
60	Efficient long-term coexpression of a hammerhead ribozyme targeted to the U5 region of HIV-1 LTR by linkage to the multidrug-resistance gene. *Oligonucleotides*, **1997**, 7, 511-22		12
59	Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. *Oncotarget*, **2016**, 7, 69804-69815	3.3	12
58	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. *Molecular Pharmacology*, **2019**, 96, 629-640	4.3	12
57	An epidermal growth factor-ricin A chain (EGF-RTA)-resistant mutant and an epidermal growth factor-Pseudomonas endotoxin (EGF-PE)-resistant mutant have distinct phenotypes. *Journal of Cellular Physiology*, **1989**, 139, 51-7	7	11
56	In situ localization of the human multidrug-resistance gene mRNA using thymine-thymine dimerized single-stranded cDNA. *Japanese Journal of Cancer Research*, **1990**, 81, 949-55		11
55	Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models. *F1000Research*, **2020**, 9,	3.6	11
54	Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function. *Drug Metabolism and Disposition*, **2019**, 47, 715-723	4	10

53	Retroviral transfer of human MDR1 gene into human T lymphocytes. *Methods in Enzymology*, **1998**, 292, 557-72	1.7	10
52	Mutant KB cells with decreased EGF receptor expression: biochemical characterization. *Journal of Cellular Physiology*, **1987**, 133, 127-34	7	10
51	Genetic characterization of human KB cell lines resistant to epidermal growth factor: Pseudomonas exotoxin conjugates. *Journal of Cellular Physiology*, **1988**, 135, 527-32	7	10
50	Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models. *Experimental Cell Research*, **2019**, 375, 106-112	4.2	10
49	Leptin Signaling Affects Survival and Chemoresistance of Estrogen Receptor Negative Breast Cancer. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	9
48	The ABCG2 Multidrug Transporter **2016**, 195-226		9
47	Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5. *Molecular Pharmaceutics*, **2014**, 11, 3452-62	5.6	9
46	Drug-resistant mutants: selection and dominance analysis. *Methods in Enzymology*, **1987**, 151, 113-21	1.7	9
45	Rous sarcoma virus transformed cells are resistant to cyclic AMP. *Journal of Cellular Physiology*, **1982**, 111, 42-8	7	9
44	Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 29609-29617	11.5	9
43	Spatial control of oxygen delivery to three-dimensional cultures alters cancer cell growth and gene expression. *Journal of Cellular Physiology*, **2019**, 234, 20608-20622	7	8
42	Human-Mouse Chimeras with Normal Expression and Function Reveal That Major Domain Swapping Is Tolerated by P-Glycoprotein (ABCB1). *Biochemistry*, **2016**, 55, 1010-23	3.2	8
41	Epidermal growth factor-dependent growth of human KB cells in a defined medium and altered growth factor requirements of KB mutants resistant to EGF-Pseudomonas exotoxin conjugates. *Journal of Cellular Physiology*, **1988**, 135, 502-8	7	8
40	The tuberous sclerosis complex subunit TBC1D7 is stabilized by Akt phosphorylation-mediated 14-3-3 binding. *Journal of Biological Chemistry*, **2018**, 293, 16142-16159	5.4	7
39	Disruption of microfilaments by cytochalasin B decreases accumulation of cisplatin in human epidermal carcinoma and liver carcinoma cell lines. *Cancer Chemotherapy and Pharmacology*, **2008**, 62, 977-84	3.5	7
38	Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier. *Scientific Reports*, **2016**, 6, 20418	4.9	7
37	Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients. *Journal of Inorganic Biochemistry*, **2015**, 149, 45-8	4.2	6
36	Putative "MDR enhancer" is located on human chromosome 20 and not linked to the MDR1 gene on chromosome 7. *Genes Chromosomes and Cancer*, **1994**, 10, 267-74	5	6

35	Identification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA. *PLoS ONE*, **2015**, 10, e0136396	3.7	5
34	In Vivo Bioluminescent Imaging of ATP-Binding Cassette Transporter-Mediated Efflux at the Blood-Brain Barrier. *Methods in Molecular Biology*, **2016**, 1461, 227-39	1.4	5
33	DNA-mediated transfer of cAMP resistance in CHO cells. *Journal of Cellular Physiology*, **1986**, 127, 89-94	7	4
32	Cross-resistance of cisplatin selected cells to anti-microtubule agents: Role of general survival mechanisms. *Translational Oncology*, **2021**, 14, 100917	4.9	4
31	Using the BacMam Baculovirus System to Study Expression and Function of Recombinant Efflux Drug Transporters in Polarized Epithelial Cell Monolayers. *Drug Metabolism and Disposition*, **2016**, 44, 180-8	4	3
30	Commentary: A delicate balance: weighing the effects of conflict-of-interest rules on intramural research at the National Institutes of Health. *Academic Medicine*, **2010**, 85, 1660-2	3.9	3
29	Codominance of cisplatin resistance in somatic cell hybrids. *Journal of Cellular Physiology*, **2003**, 196, 63-9	7	3
28	pHaMDR-DHFR bicistronic expression system for mutational analysis of P-glycoprotein. *Methods in Enzymology*, **1998**, 292, 474-80	1.7	3
27	The Evolving AML Genomic Landscape: Therapeutic Implications. *Current Cancer Drug Targets*, **2020**, 20, 532-544	2.8	3
26	Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells **2009**, 83-88		3
25	The Drug Excipient Cyclodextrin Interacts With d-Luciferin and Interferes With Bioluminescence Imaging. *Molecular Imaging*, **2016**, 15,	3.7	3
24	ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an model. *Cancer Drug Resistance (Alhambra, Calif)*, **2021**, 4, 620-633	4.5	3
23	Genetic Polymorphisms of P-glycoprotein: Echoes of Silence **2016**, 105-134		2
22	Lost in Translation: Regulation of ABCG2 Expression in Human Embryonic Stem Cells. *Journal of Stem Cell Research & Therapy*, **2014**, 4,	1	2
21	Mycoplasma Infection Mediates Sensitivity of Multidrug-Resistant Cell Lines to Tiopronin: A Cautionary Tale. *Journal of Medicinal Chemistry*, **2020**, 63, 1434-1439	8.3	2
20	Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake **2000**, 183, 108		2
19	Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities. *Journal of Investigative Dermatology*, **2019**, 139, 1985-1992.e10	4.3	1
18	How Melanoma Cells Evade Chemotherapy **2006**, 591-603		1

17	Host gene expression modulated by Zika virus infection of human-293 cells. *Virology*, **2021**, 552, 32-42	3.6	1
16	Characterization and tissue localization of zebrafish homologs of the human ABCB1 multidrug transporter		1
15	Characterization and tissue localization of zebrafish homologs of the human ABCB1 multidrug transporter.. *Scientific Reports*, **2021**, 11, 24150	4.9	1
14	The Dual Role of ABC Transporters in Drug Metabolism and Resistance to Chemotherapy **2020**, 1007-1014		0
13	Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma **2021**, 62, 16		0
12	Selectable Markers for Gene Therapy **2015**, 701-740		
11	Gil ashwell, 1916-2014. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 16232-3	11.5	
10	Rules to Prevent Conflict of Interest for Clinical Investigators Conducting Human Subjects Research **2012**, 139-146		
9	Identification of gene signatures involved in the mechanisms of multidrug resistance. *Personalized Medicine*, **2009**, 6, 133-134	2.2	
8	Multidrug Resistance I: P-Glycoprotein **2002**, 247-254		
7	Prospects for Gene Therapy of HIV Infections and AIDS291-318		
6	Clinical Applications of Gene Therapy in Cancer: Modification of Sensitivity to Therapeutic Agents429-453		
5	Gene Expression and Detection **2003**, 413-480		
4	Exploring the complexity of multidrug resistance in cancer (91.1). *FASEB Journal*, **2014**, 28, 91.1	0.9	
3	Individualized Multidrug Resistance In Acute Myeloid Leukemia. *Blood*, **2010**, 116, 2491-2491	2.2	
2	Understanding the impact of controlled oxygen delivery to 3D cancer cell culture **2020**, 661-696		
1	The Hepatocyte and the Cancer Cell: Dr Jekyll and Mr Hyde1075-1090		